

Anhang

A1 Graphische Darstellung der Therapiesequenzen

A2 Explorative Analyse des Therapieansprechens

A3 Ergebnisse der Verweildaueranalysen

A1 Graphische Darstellung der Therapiesequenzen


Farblegende:

- hellgrün = Hormontherapie
- dunkelgrün = zwei Hormontherapien gleichzeitig
- lila = CT1 (Chemotherapie mit Anthrazyklin)
- hellrot = CT2 (Chemotherapie mit Taxan)
- dunkelrot = CT3 (sonstige Chemotherapien)
- violett = CT4 (Hochdosis-Chemotherapie)







A1.1 Hormonrezeptor-positive Pat. (ER oder PR pos./uk.)

A1.1.1 MET I (n = 24)

Anhang – Graphische Darstellung der Therapiesequenzen




Anhang – Graphische Darstellung der Therapiesequenzen




A1.1.2 MET II (n = 89)


Anhang – Graphische Darstellung der Therapiesequenzen




Anhang – Graphische Darstellung der Therapiesequenzen




Anhang – Graphische Darstellung der Therapiesequenzen



Anhang – Graphische Darstellung der Therapiesequenzen




Anhang – Graphische Darstellung der Therapiesequenzen





A1.1.3 MET III (n = 37)

Anhang – Graphische Darstellung der Therapiesequenzen




Anhang – Graphische Darstellung der Therapiesequenzen






A1.1.4 MET IV(n = 50)


Anhang – Graphische Darstellung der Therapiesequenzen



Anhang – Graphische Darstellung der Therapiesequenzen
















Anhang – Graphische Darstellung der Therapiesequenzen



A1.2 Hormonrezeptor-negative Pat. (ER und PR negativ)


A1.2.1 MET I (n = 13)








Anhang – Graphische Darstellung der Therapiesequenzen



A1.2.2 MET II (n = 25)


Anhang – Graphische Darstellung der Therapiesequenzen



















A1.2.3 MET III (n = 19)

Anhang – Graphische Darstellung der Therapiesequenzen





A1.2.4 MET IV (n = 13)



A2 Explorative Analyse des Therapieansprechens

A2.1 Kontingenztafeln der Therapieansprechraten in Abhängigkeit tumorspezifischer Parameter, Therapietyp bzw. Therapiesequenz

Therapieansprechen in Abhängigkeit vom ER-Status

S1			PD	NC	PR	CR	PR/CR	ges.	p-Wert	
HT	ER neg.	abs.	3	7	0	1	1	11	0.909	
		rel.	27%	64%	0%	9%	9%	100%		
	ER pos./uk.	abs.	30	51	5	3	8	89		
		rel.	34%	57%	6%	3%	9%	100%		
CT1/2	ER neg.	abs.	15	18	14	3	17	50		0.485
		rel.	30%	36%	28%	6%	34%	100%		
	ER pos./uk.	abs.	12	26	16	3	19	57		
		rel.	21%	46%	28%	5%	33%	100%		
CT3	ER neg.	abs.	8	19	6	3	9	36	0.818	
		rel.	22%	53%	17%	8%	25%	100%		
	ER pos./uk.	abs.	7	15	3	2	5	27		
		rel.	26%	56%	11%	7%	19%	100%		
ges.	ER neg.	abs.	26	44	20	7	27	97		0.193
		rel.	27%	45%	21%	7%	28%	100%		
	ER pos./uk.	abs.	49	92	24	8	32	173		
		rel.	28%	53%	14%	5%	18%	100%		
S2			PD	NC	PR	CR	PR/CR	ges.	p-Wert	
HT	ER neg.	abs.	11	7	0	1	1	19	0.673	
		rel.	58%	37%	0%	5%	5%	100%		
	ER pos./uk.	abs.	33	29	5	2	7	69		
		rel.	48%	42%	7%	3%	10%	100%		
CT1/2	ER neg.	abs.	20	15	3	2	5	40		0.401
		rel.	50%	38%	8%	5%	13%	100%		
	ER pos./uk.	abs.	15	19	5	3	8	42		
		rel.	36%	45%	12%	7%	19%	100%		
CT3	ER neg.	abs.	15	5	1	0	1	21	0.405	
		rel.	71%	24%	5%	0%	5%	100%		
	ER pos./uk.	abs.	17	13	2	0	2	32		
		rel.	53%	41%	6%	0%	6%	100%		
ges.	ER neg.	abs.	46	27	4	3	7	80		0.224
		rel.	58%	34%	5%	4%	9%	100%		
	ER pos./uk.	abs.	65	61	12	5	17	143		
		rel.	45%	43%	8%	3%	12%	100%		
S3			PD	NC	PR	CR	PR/CR	ges.	p-Wert	
HT	ER neg.	abs.	13	5	0	0	0	18	0.064	
		rel.	72%	28%	0%	0%	0%	100%		
	ER pos./uk.	abs.	19	26	1	1	2	47		
		rel.	40%	55%	2%	2%	4%	100%		
CT1/2	ER neg.	abs.	10	4	1	1	2	16		0.363
		rel.	63%	25%	6%	6%	13%	100%		
	ER pos./uk.	abs.	12	13	2	1	3	28		
		rel.	43%	46%	7%	4%	11%	100%		
CT3	ER neg.	abs.	4	6	4	0	4	14	0.083	
		rel.	29%	43%	29%	0%	29%	100%		
	ER pos./uk.	abs.	12	11	1	0	1	24		
		rel.	50%	46%	4%	0%	4%	100%		
ges.	ER neg.	abs.	27	15	5	1	6	48		0.065
		rel.	56%	31%	10%	2%	13%	100%		
	ER pos./uk.	abs.	43	50	4	2	6	99		
		rel.	43%	51%	4%	2%	6%	100%		
ges.			PD	NC	PR	CR	PR/CR	ges.	p-Wert	
HT	ER neg.	abs.	27	19	0	2	2	48	0.110	
		rel.	56%	40%	0%	4%	4%	100%		
	ER pos./uk.	abs.	82	106	11	6	17	205		
		rel.	40%	52%	5%	3%	8%	100%		
CT1/2	ER neg.	abs.	45	37	18	6	24	106		0.144
		rel.	42%	35%	17%	6%	23%	100%		
	ER pos./uk.	abs.	39	58	23	7	30	127		
		rel.	31%	46%	18%	6%	24%	100%		
CT3	ER neg.	abs.	27	30	11	3	14	71	0.204	
		rel.	38%	42%	15%	4%	20%	100%		
	ER pos./uk.	abs.	36	39	6	2	8	83		
		rel.	43%	47%	7%	2%	10%	100%		
ges.	ER neg.	abs.	99	86	29	11	40	225		0.029
		rel.	44%	38%	13%	5%	18%	100%		
	ER pos./uk.	abs.	157	203	40	15	55	415		
		rel.	38%	49%	10%	4%	13%	100%		

Therapieansprechen in Abhängigkeit vom PR-Status

S1			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	PR neg.	abs.	12	12	0	0	0	24	0.051
		rel.	50%	50%	0%	0%	0%	100%	
	PR pos./uk.	abs.	21	46	5	4	9	76	100%
		rel.	28%	61%	7%	5%	12%	100%	
CT1/2	PR neg.	abs.	15	18	14	2	16	49	0.476
		rel.	31%	37%	29%	4%	33%	100%	
	PR pos./uk.	abs.	12	26	16	4	24	58	100%
		rel.	21%	45%	28%	7%	34%	100%	
CT3	PR neg.	abs.	9	19	5	1	24	34	0.617
		rel.	26%	56%	15%	3%	18%	100%	
	PR pos./uk.	abs.	6	15	4	4	24	29	100%
		rel.	21%	52%	14%	14%	28%	100%	
ges.	PR neg.	abs.	36	49	19	3	24	107	0.216
		rel.	34%	46%	18%	3%	21%	100%	
	PR pos./uk.	abs.	39	87	25	12	57	163	100%
		rel.	24%	53%	15%	7%	23%	100%	
S2			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	PR neg.	abs.	14	6	1	0	1	21	0.209
		rel.	67%	29%	5%	0%	5%	100%	
	PR pos./uk.	abs.	30	30	4	3	7	67	100%
		rel.	45%	45%	6%	4%	10%	100%	
CT1/2	PR neg.	abs.	23	18	2	2	4	45	0.092
		rel.	51%	40%	4%	4%	9%	100%	
	PR pos./uk.	abs.	12	16	6	3	9	37	100%
		rel.	32%	43%	16%	8%	24%	100%	
CT3	PR neg.	abs.	18	5	0	0	0	23	0.044
		rel.	78%	22%	0%	0%	0%	100%	
	PR pos./uk.	abs.	14	13	3	0	3	30	100%
		rel.	47%	43%	10%	0%	10%	100%	
ges.	PR neg.	abs.	55	29	3	2	5	89	0.008
		rel.	62%	33%	3%	2%	6%	100%	
	PR pos./uk.	abs.	56	59	13	6	19	134	100%
		rel.	42%	44%	10%	4%	14%	100%	
S3			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	PR neg.	abs.	16	9	0	0	0	25	0.132
		rel.	64%	36%	0%	0%	0%	100%	
	PR pos./uk.	abs.	16	22	1	1	2	40	100%
		rel.	40%	55%	3%	3%	5%	100%	
CT1/2	PR neg.	abs.	9	6	0	0	0	15	0.217
		rel.	60%	40%	0%	0%	0%	100%	
	PR pos./uk.	abs.	13	11	3	2	5	29	100%
		rel.	45%	38%	10%	7%	17%	100%	
CT3	PR neg.	abs.	4	6	1	0	1	11	0.723
		rel.	36%	55%	9%	0%	9%	100%	
	PR pos./uk.	abs.	12	11	4	0	4	27	100%
		rel.	44%	41%	15%	0%	15%	100%	
ges.	PR neg.	abs.	29	21	1	0	1	51	0.073
		rel.	57%	41%	2%	0%	2%	100%	
	PR pos./uk.	abs.	41	44	8	3	11	96	100%
		rel.	43%	46%	8%	3%	11%	100%	
ges.			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	PR neg.	abs.	42	27	1	0	1	70	0.001
		rel.	60%	39%	1%	0%	1%	100%	
	PR pos./uk.	abs.	67	98	10	8	18	183	100%
		rel.	37%	54%	5%	4%	10%	100%	
CT1/2	PR neg.	abs.	47	42	16	4	20	109	0.076
		rel.	43%	39%	15%	4%	18%	100%	
	PR pos./uk.	abs.	37	53	25	9	34	124	100%
		rel.	30%	43%	20%	7%	27%	100%	
CT3	PR neg.	abs.	31	30	6	1	7	68	0.363
		rel.	46%	44%	9%	1%	10%	100%	
	PR pos./uk.	abs.	32	39	11	4	15	86	100%
		rel.	37%	45%	13%	5%	17%	100%	
ges.	PR neg.	abs.	120	99	23	5	28	247	<0.001
		rel.	49%	40%	9%	2%	11%	100%	
	PR pos./uk.	abs.	136	190	46	21	67	393	100%
		rel.	35%	48%	12%	5%	17%	100%	

Therapieansprechen in Abhängigkeit vom Her2neu- Status

S1			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	Her2-neu 0-2/uk.	abs.	28	47	5	4	9	84	0.348
		rel.	33%	56%	6%	5%	11%	100%	
Her2-neu 3	abs.	5	11	0	0	0	16		
	rel.	31%	69%	0%	0%	0%	100%		
CT1/2	Her2-neu 0-2/uk.	abs.	22	41	24	4	28	91	0.132
		rel.	24%	45%	26%	4%	31%	100%	
Her2-neu 3	abs.	5	3	6	2	8	16		
	rel.	31%	19%	38%	13%	50%	100%		
CT3	Her2-neu 0-2/uk.	abs.	10	28	8	4	12	50	0.367
		rel.	20%	56%	16%	8%	24%	100%	
Her2-neu 3	abs.	5	6	1	1	2	13		
	rel.	38%	46%	8%	8%	15%	100%		
ges.	Her2-neu 0-2/uk.	abs.	60	116	37	12	49	225	0.348
		rel.	27%	52%	16%	5%	22%	100%	
Her2-neu 3	abs.	15	20	7	3	10	45		
	rel.	33%	44%	16%	7%	22%	100%		
S2			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	Her2-neu 0-2/uk.	abs.	37	33	5	3	8	78	0.324
		rel.	47%	42%	6%	4%	10%	100%	
Her2-neu 3	abs.	7	3	0	0	0	10		
	rel.	70%	30%	0%	0%	0%	100%		
CT1/2	Her2-neu 0-2/uk.	abs.	27	31	6	4	10	68	0.248
		rel.	40%	46%	9%	6%	15%	100%	
Her2-neu 3	abs.	8	3	2	1	3	14		
	rel.	57%	21%	14%	7%	21%	100%		
CT3	Her2-neu 0-2/uk.	abs.	22	17	3	0	3	42	0.065
		rel.	52%	40%	7%	0%	7%	100%	
Her2-neu 3	abs.	10	1	0	0	0	11		
	rel.	91%	9%	0%	0%	0%	100%		
ges.	Her2-neu 0-2/uk.	abs.	86	81	14	7	21	188	0.018
		rel.	46%	43%	7%	4%	11%	100%	
Her2-neu 3	abs.	25	7	2	1	3	35		
	rel.	71%	20%	6%	3%	9%	100%		
S3			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	Her2-neu 0-2/uk.	abs.	21	28	0	1	1	50	0.044
		rel.	42%	56%	0%	2%	2%	100%	
Her2-neu 3	abs.	11	3	1	0	1	15		
	rel.	73%	20%	7%	0%	7%	100%		
CT1/2	Her2-neu 0-2/uk.	abs.	22	14	3	2	5	41	0.078
		rel.	54%	34%	7%	5%	12%	100%	
Her2-neu 3	abs.	0	3	0	0	0	3		
	rel.	0%	100%	0%	0%	0%	100%		
CT3	Her2-neu 0-2/uk.	abs.	14	14	4	0	4	32	0.886
		rel.	44%	44%	13%	0%	13%	100%	
Her2-neu 3	abs.	2	3	1	1	1	6		
	rel.	33%	50%	17%	0%	17%	100%		
ges.	Her2-neu 0-2/uk.	abs.	57	56	7	3	10	123	0.759
		rel.	46%	46%	6%	2%	8%	100%	
Her2-neu 3	abs.	13	9	2	0	2	24		
	rel.	54%	38%	8%	0%	8%	100%		
ges.			PD	NC	PR	CR	PR/CR	ges.	p-Wert
HT	Her2-neu 0-2/uk.	abs.	86	108	10	8	18	212	0.146
		rel.	41%	51%	5%	4%	8%	100%	
Her2-neu 3	abs.	23	17	1	0	1	41		
	rel.	56%	41%	2%	0%	2%	100%		
CT1/2	Her2-neu 0-2/uk.	abs.	71	86	33	10	43	200	0.170
		rel.	36%	43%	17%	5%	22%	100%	
Her2-neu 3	abs.	13	9	8	3	11	33		
	rel.	39%	27%	24%	9%	33%	100%		
CT3	Her2-neu 0-2/uk.	abs.	46	59	15	4	19	124	0.175
		rel.	37%	48%	12%	3%	15%	100%	
Her2-neu 3	abs.	17	10	2	1	3	30		
	rel.	57%	33%	7%	3%	10%	100%		
ges.	Her2-neu 0-2/uk.	abs.	203	253	58	22	80	536	0.033
		rel.	38%	47%	11%	4%	15%	100%	
Her2-neu 3	abs.	53	36	11	4	15	104		
	rel.	51%	35%	11%	4%	14%	100%		

Therapieansprechen in Abhängigkeit des Typs der Vorgängertherapie


HT		PD	NC	PR	CR	PR/CR	ges.	p-Wert (Test auf Sequenzabh.)
nach HT (S2)	abs.	22	19	1	1	2	43	p=0.159
	rel.	51%	44%	2%	2%	5%	100%	
nach HT (S3)	abs.	9	14	1	0	1	24	
	rel.	38%	58%	4%	0%	4%	100%	
nach HT (ges.)	abs.	31	33	2	1	3	67	
	rel.	46%	49%	3%	1%	4%	100%	
nach CT1/2/4 (S2)	abs.	16	9	4	2	6	31	
	rel.	52%	29%	13%	6%	19%	100%	
nach CT1/2/4 (S3)	abs.	11	12	0	1	1	24	
	rel.	46%	50%	0%	4%	4%	100%	
nach CT1/2/4 (ges.)	abs.	27	21	4	3	7	55	
	rel.	49%	38%	7%	5%	13%	100%	
nach CT3 (S2)	abs.	6	8	0	0	0	14	
	rel.	43%	57%	0%	0%	0%	100%	
nach CT3 (S3)	abs.	12	5	0	0	0	17	
	rel.	71%	29%	0%	0%	0%	100%	
nach CT3 (ges.)	abs.	18	13	0	0	0	31	
	rel.	58%	42%	0%	0%	0%	100%	
ges.	abs.	109	125	11	8	19	253	
	rel.	43%	49%	4%	3%	8%	100%	

CT1/2/4		PD	NC	PR	CR	PR/CR	ges.	p-Wert (Test auf Sequenzabh.)
nach HT (S2)	abs.	8	14	3	2	5	27	p=0.037
	rel.	30%	52%	11%	7%	19%	100%	
nach HT (S3)	abs.	8	8	2	1	3	19	
	rel.	42%	42%	11%	5%	16%	100%	
nach HT (ges.)	abs.	16	22	5	3	8	46	
	rel.	35%	48%	11%	7%	17%	100%	
nach CT1/2/4 (S2)	abs.	9	14	4	2	6	29	
	rel.	31%	48%	14%	7%	21%	100%	
nach CT1/2/4 (S3)	abs.	7	4	1	1	2	13	
	rel.	54%	31%	8%	8%	15%	100%	
nach CT1/2/4 (ges.)	abs.	16	18	5	3	8	42	
	rel.	38%	43%	12%	7%	19%	100%	
nach CT3 (S2)	abs.	18	6	1	1	2	26	
	rel.	69%	23%	4%	4%	8%	100%	
nach CT3 (S3)	abs.	7	5	0	0	0	12	
	rel.	58%	42%	0%	0%	0%	100%	
nach CT3 (ges.)	abs.	25	11	1	1	2	38	
	rel.	66%	29%	3%	3%	5%	100%	
ges.	abs.	84	95	41	13	54	233	
	rel.	36%	41%	18%	6%	23%	100%	


CT3		PD	NC	PR	CR	PR/CR	ges.	p-Wert (Test auf Sequenzabh.)
nach HT (S2)	abs.	8	5	0	0	0	13	p=0.039
	rel.	62%	38%	0%	0%	0%	100%	
nach HT (S3)	abs.	5	8	2	0	2	15	
	rel.	33%	53%	13%	0%	13%	100%	
nach HT (ges.)	abs.	13	13	2	0	2	28	
	rel.	46%	46%	7%	0%	7%	100%	
nach CT1/2/4 (S2)	abs.	22	7	1	0	1	30	
	rel.	73%	23%	3%	0%	3%	100%	
nach CT1/2/4 (S3)	abs.	7	8	2	0	2	17	
	rel.	41%	47%	12%	0%	12%	100%	
nach CT1/2/4 (ges.)	abs.	29	15	3	0	3	47	
	rel.	62%	32%	6%	0%	6%	100%	
nach CT3 (S2)	abs.	2	6	2	0	2	10	
	rel.	20%	60%	20%	0%	20%	100%	
nach CT3 (S3)	abs.	4	1	1	0	1	6	
	rel.	67%	17%	17%	0%	17%	100%	
nach CT3 (ges.)	abs.	6	7	3	0	3	16	
	rel.	38%	44%	19%	0%	19%	100%	
ges.	abs.	63	69	17	5	22	154	
	rel.	41%	45%	11%	3%	14%	100%	

A2.2 Klassifikationsbäume (CART)


Firstline-Therapiestrategie [HT vs. CT1/2 vs. CT3] in Abhängigkeit patienten- bzw. tumorspezifischer Parameter



**Secondline-Therapieansprechen [PD vs. NC vs. PR/CR]
in Abhängigkeit tumorspez. Parameter**




Thirdline-Therapieansprechen [PD vs. NC vs. PR/CR] in Abhängigkeit tumorspez. Parameter bzw. Therapiesequenz




A3 Ergebnisse der Verweildaueranalysen

A3.1 Survival-CART


Zeit bis zur Progression (S1) in Abhängigkeit tumorspez. Parameter bzw. Therapietyp



Gesamtüberleben ab Metastasierung in Abhängigkeit von Prognosefaktoren und Firstline-Therapieerfolg





Gesamtüberleben ab Metastasierung in Abhängigkeit von Prognosefaktoren sowie First- u. Secondline-Therapieerfolg




A3.2 Kaplan-Meier Kurven









A3.2.1 Zeit bis zur Risikoveränderung













A3.2.2 Zeit bis zur Progression (S1-S3), Restüberlebenszeit nach 3 palliativen Therapielinien


























A3.2.3 Gesamtüberlebenszeit ab Metastasierung
















A3.3 Adjustierte Hazard-Kurven der übergangsspezifischen Cox-Modelle








A3.3.1 Zeit bis zur Progression (S1- S3) bzw. Restüberlebenszeit

















Adjust. Hazard-Kurve nach vor.Respd.(S 2)









Adjust. Hazard-Kurve nach vor.Respd.(S 3)





Adjust. Hazard-Kurve nach vor.Respd.(SD)







A3.3.2 Gesamtüberlebenszeit ab Metastasierung








A3.4 Adjustierte marginale Multi-State Hazard-Kurven







A3.5 Modelldiagnostik-Residuenplots


A3.5.1 Cox-Modell für die Zeit bis zur Progression (S1)

Schönfeldresiduen







Martingalresiduen



Deviance-Residuen




Delta-Beta-Residuen




A3.5.2 Multi-State-Modell

Martingal Residuen





Deviance-Residuen



A3.5.3 Gesamtüberleben ab Metastasierung

Schönfeldresiduen





Delta-Beta-Residuen

